

# New Products - Lucassin

---

Lucassin (**terlipressin**) is a synthetic vasopressin analogue that acts as a systemic vasoconstrictor, via vasopressin 1a (V<sub>1a</sub>) receptors, both as a prodrug for lysine-vasopressin and having pharmacologic activity on its own, albeit of lower potency than lysine-vasopressin. Terlipressin increases mean arterial pressure and decreases heart rate while increasing systemic vascular resistance. In hepatorenal syndrome (HRS) patients with hyperdynamic circulation, the V<sub>1</sub> receptor-mediated vasoconstrictor activity of terlipressin, particularly in the splanchnic area, results in an increase in mean arterial pressure, normalisation of endogenous vasoconstrictor systems (renin-angiotensin-aldosterone and sympathetic nervous system), and an increase in renal blood flow. The therapeutic rationale for treatment of HRS with terlipressin is that these effects may result in improved renal function. Lucassin is indicated for the treatment of patients with HRS type 1 who are actively being considered for a liver transplant. Lucassin is available as a powder for injection in a single use vial containing 85 mg of terlipressin.

*This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.*